Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  American Journal of Physiology. Heart and Circulatory Physiology

• Publication date

  2005-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1152/AJPHEART.00078.2005PMID 15879491
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Asymmetric Dimethylarginine Produces Vascular Lesions in Endothelial Nitric Oxide Synthase–Deficient Mice: Involvement of Renin-Angiotensin System and Oxidative Stress

  2004cited by this paper
• Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E2–Dependent Matrix Metalloproteinase Activity

  2004cited by this paper
• Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.

  2004cited by this paper
• Cardioprotective effects of carvedilol on acute autoimmune myocarditis

  2004cited by this paper
• Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation

  2004cited by this paper
• Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.

  2004cited by this paper
• Cardioprotective effects of carvedilol on acute autoimmune myocarditis.

  2003cited by this paper
• Angiotensin II type-1 receptor antagonist inhibits vascular phenotypic change and remodeling in intramyocardial arteries by reducing oxidative stress through upregulation of superoxide dismutase

  2003cited by this paper
• Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis : Concomitant suppression of the expression of dendritic cells

  2003influential reference
• Beneficial effects of low-dose benidipine in acute autoimmune myocarditis: suppressive effects on inflammatory cytokines and inducible nitric oxide synthase.

  2003cited by this paper
• Angiotensin II Receptor–Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179

  2002cited by this paper
• Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients

  2002cited by this paper
• Overexpression of Thioredoxin-1 in Transgenic Mice Attenuates Adriamycin-Induced Cardiotoxicity

  2002cited by this paper
• Effects of Angiotensin II Infusion on the Expression and Function of NAD(P)H Oxidase and Components of Nitric Oxide/cGMP Signaling

  2002influential reference
• Fc Receptor–Mediated Inhibitory Effect of Immunoglobulin Therapy on Autoimmune Giant Cell Myocarditis: Concomitant Suppression of the Expression of Dendritic Cells

  2001cited by this paper
• Immunoglobulin treatment prevents congestive heart failure in murine encephalomyocarditis viral myocarditis associated with reduction of inflammatory cytokines.

  2001cited by this paper
• Angiotensin II Type 1 Receptor Blockers

  2001influential reference
• Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure.

  2000cited by this paper
• Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes.

  2000cited by this paper
• Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

  2000cited by this paper
• From Myocarditis to Cardiomyopathy: Mechanisms of Inflammation and Cell Death

  1999cited by this paper
• Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.

  1999cited by this paper
• Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system.

  1999cited by this paper
• Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.

  1999cited by this paper
• From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future.

  1999cited by this paper
• Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice.

  1997cited by this paper
• Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist.

  1995influential reference
• Interleukin 1 or tumor necrosis factor can promote Coxsackie B3-induced myocarditis in resistant B10.A mice

  1992cited by this paper
• A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction.

  1990cited by this paper
• Angiotensin II is chemotactic for a T-cell subset which can express migration inhibition factor activity in murine schistosomiasis mansoni.

  1987cited by this paper
• Captopril and immune regulation.

  1984cited by this paper

• Angiotensin II receptor 1 controls profibrotic Wnt/β-catenin signalling in experimental autoimmune myocarditis

  2021cites this paper
• Protective Effects of Olmesartan and L-carnitine on Doxorubicin-Induced Cardiotoxicity in Rats.

  2020cites this paper
• Deneysel otoi̇mmün mi̇yokardi̇t modeli̇nde ozonun tedavi̇ edi̇ci̇ etki̇si̇ni̇n araştırılması

  2019cites this paper
• Fibroblast growth factor 21 protects against pathological cardiac remodeling by modulating galectin‐3 expression

  2019cites this paper
• Therapies to limit myocardial injury in animal models of myocarditis: a systematic review and meta-analysis

  2019cites this paper
• T Cells and Hypertension: Solved and Unsolved Mysteries Regarding the Female Rat.

  2018cites this paper
• Recent advances in the management of autoimmune myocarditis: insights from animal studies.

  2016cites this paper
• Anti‐inflammatory role of obestatin in autoimmune myocarditis

  2016cites this paper
• N-Acetylcysteine Ameliorates Experimental Autoimmune Myocarditis in Rats via Nitric Oxide

  2015cites this paper
• Experimental drugs for treatment of autoimmune myocarditis.

  2014cites this paper
• Angiotensin II receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice.

  2013cites this paper
• マウスの実験的動脈硬化に対する3種類のβアドレナリン受容体遮断薬 (プロプラノロール, メトプロロール, カルベジロール) の効果

  2013cites this paper
• Erythromycin treatment suppresses myocardial injury in autoimmune myocarditis in rats via suppression of superoxide production.

  2013cites this paper
• of the skeletal muscle in type 2 diabetic mice exercise capacity and impaired mitochondrial function Angiotensin II receptor blocker improves the lowered

  2013cites this paper
• The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice

  2013cites this paper
• Curcumin and enalapril ameliorate renal failure by antagonizing inflammation in 5/6 nephrectomized rats: role of phospholipase and cyclooxygenase.

  2012cites this paper
• Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production

  2012cites this paper
• Olmesartan Attenuates the Impairment of Endothelial Cells Induced by Oxidized Low Density Lipoprotein through Downregulating Expression of LOX-1

  2012cites this paper
• Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.

  2011cites this paper
• Connecting chronic and recurrent stress to vascular dysfunction: no relaxed role for the renin-angiotensin system.

  2011cites this paper
• Angiotensin II induces NF-κB, JNK and p38 MAPK activation in monocytic cells and increases matrix metalloproteinase-9 expression in a PKC- andRho kinase-dependent manner.

  2011cites this paper
• Olmesartan, an AT1 Antagonist, Attenuates Oxidative Stress, Endoplasmic Reticulum Stress and Cardiac Inflammatory Mediators in Rats with Heart Failure Induced by Experimental Autoimmune Myocarditis

  2011cites this paper
• What causes a broken heart--molecular insights into heart failure.

  2010cites this paper
• Adenosine pretreatment attenuates angiotensin II-mediated p38 MAPK activation in a protein kinase A dependent manner

  2010cites this paper
• Autoimmune Murine Myocarditis and Immunomodulatory Interventions

  2010cites this paper
• Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy

  2010cites this paper
• Cardiac-Specific Activation of Angiotensin II Type 1 Receptor–Associated Protein Completely Suppresses Cardiac Hypertrophy in Chronic Angiotensin II–Infused Mice

  2010cites this paper
• Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy

  2010cites this paper
• Angiotensin II Differentially Induces Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Production and Disturbs MMP/TIMP Balance

  2010cites this paper
• Immunosuppressive effect of angiotensin receptor blocker on stimulation of mice CTLs by angiotensin II.

  2009cites this paper
• N-acetylcysteine reduces the severity of atherosclerosis in apolipoprotein E-deficient mice by reducing superoxide production.

  2009cites this paper
• Effects of angiotensin-II receptor blockers on experimental autoimmune myocarditis.

  2009cites this paper
• Novel therapeutic targets in viral myocarditis

  2008cites this paper
• L‐arginine ameliorates experimental autoimmune myocarditis by maintaining extracellular matrix and reducing cytotoxic activity of lymphocytes

  2008cites this paper
• Naloxone, an Opiate Receptor Antagonist, Ameliorates Acute Experimental Autoimmune Myocarditis by Reducing Cytotoxic Activities

  2008cites this paper
• Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis.

  2008cites this paper
• Effect of Olmesartan on Tissue Expression Balance Between Angiotensin II Receptor and Its Inhibitory Binding Molecule

  2008cites this paper
• Macrophage Infiltration and Cellular Proliferation in the Non-Ischemic Kidney and Heart following Prolonged Unilateral Renal Ischemia

  2007cites this paper
• Renin: at the heart of the mast cell

  2007cites this paper
• Effect of Olmesartan on Oxidative Stress in Hemodialysis Patients

  2007cites this paper
• EMERGING DRUG THERAPIES FOR HEART FAILURE

  2006cites this paper